Amir Fathi, MD, is an Associate Professor of Medicine at Harvard Medical School and the Program Director of the Center for Leukemia and Massachusetts General Hospital. He specializes in the treatment of patients with acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloproliferative diseases. Dr. Fathi’s research focuses of the development of novel treatments for acute leukemias, with particular interest in FLT3 inhibition, aurora kinase inhibition, and antibody-drug conjugates, and he currently serves as primary investigator of several clinical trials.

Louis Diehl, MD, is a Professor of Medicine at Duke University Medical School and a Member of the Duke Cancer Institute in Durham, North Carolina. He specializes in the treatment of patients with Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and other hematological malignancies. Dr. Diehl has authored or coauthored more than 300 publications focused on developing novel treatments and improving outcomes for patients with lymphoma and other hematological diseases.

Morie Gertz, MD, is the Roland Seidler Jr. Professor in the Department of Medicine and Chair of General Internal Medicine at the Mayo Clinic in Rochester, Minnesota. He specializes in the treatment of patients with Waldenstrom macroglobulinemia, amyloidosis, and multiple myeloma, including those undergoing stem cell transplantation. Dr. Gertz serves as a member of the American Board of Internal Medicine’s Hematology Approval Committee, and he has authored or coauthored more than 700 manuscripts focusing on research for hematological malignancies.

John Leonard, MD, is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, the Senior Associate Dean for Innovation and Initiatives, and the Executive Vice Chairman of the Department of Medicine at Weill Cornell Medicine in New York. In addition, he is an attending physician at New York Presbyterian Hospital. Dr. Leonard specializes in the treatment of patients with mantle cell lymphoma, Hodgkin lymphoma, multiple myeloma, and other hematological malignancies. He has served as an investigator of numerous clinical trials focusing on novel therapeutics for hematological cancers.

Mikkael Sekeres, MD, is a Professor of Medicine and Chief of the Division of Hematology at the University of Miami Health System, where he specializes in the treatment of patients with myelodysplastic syndromes and older patients with acute myeloid leukemia. Dr. Sekeres has served as primary study investigator of dozens of clinical trials, and he has authored or coauthored over 400 manuscripts, 600 meeting abstracts, and 8 books. He serves on the Executive Committee of the American Society of Hematology and as a member of Southwest Oncology Group Leukemia Committee.